32P and acute leukemia: development of leukemia in a patient with hemoglobin Yakima.
نویسندگان
چکیده
In 1954 a then 31-yr-old male was found to have erythrocytosis. Over the ensuing decade he received 72 mCi32P. In 1964 his daughters were found to have erythrocytosis. Further investigation led to the discovery of hemoglobin Yakima, a variant with high oxygen affinity. He received no further therapy and was well until 1975, when he developed the preleukemic syndrome. Within 12 mo. he developed acute nonlymphocytic leukemia accompanied by fetal erythropoiesis. Because the inital discovery of this type of hemoglobinopathy came 27 yr after the introduction of 32P for use in the treatment of polycythemia vera, and because there are now known to be more than 39 different high-oxygen-affinity hemoglobins, we anticipate that more patients such as ours have been exposed to 32P. The exposed population should be cosely followed, since this will likely permit assessment of the risk of 32P-induced leukemia in a nonneoplastic condition.
منابع مشابه
Development of Leukemia in a Patient With Hemoglobin Yakima
In 1954 a then 31 -yr-old male was found to have erythrocytosis. Over the ensuing decade he received 72 mCi 32P. In 1964 his daughters were found to have erythrocytosis. Further investigation led to the discovery of hemoglobin Yakima, a variant with high oxygen affinity. He received no further therapy and was well until 1975, when he developed the preleu. kemic syndrome. Within 12 mo he develop...
متن کاملTreatment of a Child with Refractory Acute Myeloid Leukemia with Humanized Anti-CD33 Monoclonal Antibody: A Case Report and Review of Drug Development
Background: The induction chemotherapy regimen for acute myeloid leukemia has evolved as once induction is completed patients progress through the consolidation phase and achieve remission in 76% of cases. For patients with relapsed or refractory disease, alternative chemotherapy agents are available. Monoclonal antibody therapy with biological agents, such as the immunotoxin gemtuzumab ozog...
متن کاملThe relation between end of induction minimal residual disease and different risk factors in patients with acute lymphoblastic leukemia
Background: Malignant disorder with B or T stem cell basis leads to development and continuation of acute lymphoblastic leukemia (ALL) due to aggregation of blast cells in bone marrow. The environmental, genetic, and demographic factors may influence the disease relapse. The objective of this study was to assess the relation between end of induction minimal residual disease and different risk f...
متن کاملInvestigation of Leptin, Leukemia Inhibitory Factor (LIF), and IL-6 Serum Levels in Myeloid Leukemia
Background: Leptin has been implicated in the differentiation and proliferation of hematopoietic cells. Leukemia inhibitory factor (LIF) may play an important role, along with Interleukin-6 (IL-6) and granulocyte colony stimulating factor (G- CSF), in the regulation of early hematopoietic stem cells. The aim of the study was to evaluate serum level of leptin, LIF, and IL-6 in myeloid leukemia p...
متن کاملPROGNOSTIC VALUE OF MYELOID ANTIGEN EXPRESSION IN ACUTE LYMPHOBLASTIC LEUKEMIA
Expression of cell surface molecules associated with lymphoid and myeloid lineage differentiation on the blasts of 53 patients with acute lymphoblastic leukemia (ALL) was investigated. 1.9% of cases were only HLA"7DR+ 7.6% were HLA-DR+, CDI9+ 22.6% were HLA-DR+, CDI9+, CDI0+ 30.2% were HLADR+, CDI9+, CDlO±, CD20+ and 37.7% were HLA-DR±, CD7+, CD5±. Aberrant expression of one or more myeloi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Blood
دوره 52 2 شماره
صفحات -
تاریخ انتشار 1978